Find Clinical Trial

Ivosidenib (IVO) monotherapy and azacitidine (AZA) monotherapy in patients with hypomethylating agent (HMA) naive myelodysplastic syndromes (MDS) with an IDH1 mutation


← Back
Study Phase

Phase 3

Therapeutic Area

Cancers

IndicationMyelodysplastic Syndrome
SponsorInstitut de Recherches Internationales Servier (I.R.I.S.)
Active substance/
Medical device

Ivosidenib

Active Substance CodeS09531
Protocol CodeS095031-178
Eu CT2023-510155-37-00
NCT CodeNCT06465953
Other Protocol Name :PyramIDH


Documents and links

Results are not yet available.



Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2025 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility